Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Has announcements × pomalidomide × Clear all

Phase

Status

Sponsor Class

INDUSTRY 3 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

daratumumab 3 Dexamethasone 3 Cytarabine 2 Bortezomib 2 Asparaginase 2 pomalidomide 1 pembrolizumab 1 pegaspargase 1 merphos 1 etoposide phosphate 1 darlin protein, Dictyostelium 1 calaspargase pegol 1 bosutinib 1 asparaginase erwinia chrysanthemi recombinant 1 X-Rays 1 Vincristine 1 Thalidomide 1 Spinal Puncture 1 Specimen Handling 1 Pemetrexed 1 Mitoxantrone 1 Methotrexate 1 Leucovorin 1 Lenalidomide 1 Inotuzumab Ozogamicin 1 Gemtuzumab 1 Etoposide 1 Daunorubicin 1 Cyclophosphamide 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03180736 2025-12-19

EMN14

European Myeloma Network B.V.

Phase 3 Completed

304 enrolled 19 charts 1 FDA

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡